Cytosorbents Corporation (CTSO)

From the record

Cytosorbents Corporation's filings since 2017 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2026-07-06); a warning not to rely on past financial statements (8-K item 4.02, the latest 2025-03-31) (its current reports).

From the record

Cytosorbents Corporation's 10 filed years say what it did: revenue went from $8 million in fiscal 2016 to $37 million in fiscal 2025, up 18.2% a year; it rose in 7 of 9 years; the deepest fall was 28% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cytosorbents Corporation lost about 139 cents for every dollar of shareholders' money, and gross profitability: its products earned about 60 cents per dollar of everything the company owns. Leverage: it owed about 87 cents per dollar of assets, and net share issuance: its share count grew 14.3% over the year (the filed statements).

From the record

Cytosorbents Corporation's standing among 109 graded names in its industry family: revenue of $37 million in fiscal 2025 ranks in the bottom 34% by size; a net margin of -22.1% ranks in the bottom 49%; revenue growth of 2.2% a year over the last 3 filed years ranks in the bottom 26% (its annual reports).

From the record

Cytosorbents Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Chan, Phillip P. (Chief Executive Officer, as filed), filing under that title since 2009-01-09, 17.8 years (top 4% of its family); the 4 officers and directors filing in the last fifteen months have been on the record a median of 14.9 years (top 2%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 4 people in charge now (top 48%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Cytosorbents Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against debt of $17 million leaves -23.6% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is -33.8% of revenue (bottom 36%); a gross margin of 71.5% (top 29%) (its annual report).

From the record

Cytosorbents Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 2.2% a year over the last three filed years against 18.2% over all 10, slowing (bottom 22% of its family); the newest year grew 4.1% (bottom 28%); research spending grew 21.3% a year (top 21%); capital spending grew -70% a year (bottom 5%) (its annual reports). Cytosorbents Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Cytosorbents Corporation's newest year against its own record: revenue of $37 million in fiscal 2025 came in 2.8% above the $36 million its prior three years' pace pointed to (top 32% of its family); net income of $8 million against a prior three-year average of $28 million (top 26%); a net margin of -22.1% against -82.3% before (top 16%) (its annual reports).